Merck & Co. highlights oncology pipeline data, shares hold steady on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 08:34.

Merck & Co., Inc. (US58933Y1055) enters the week with fresh attention on its KEYTRUDA-based oncology pipeline. Five-year follow-up data from the KEYNOTE-942 trial with partner Moderna underline the potential of the personalized cancer vaccine V940 combined with KEYTRUDA, while MRK shares recently traded near 115 dollars on the NYSE according to market data.

What recent data show

Merck and Moderna earlier highlighted five-year follow-up results from the Phase 2b KEYNOTE-942 study, which evaluates the individualized neoantigen therapy V940 (mRNA-4157) in combination with KEYTRUDA in resected high-risk melanoma, showing sustained clinical benefit signals over time according to a recent market summary that cites the follow-up dataset.TrendSpider market overview referencing KEYNOTE-942 follow-up The trial builds on earlier data presented at major oncology congresses, where the combination reduced the risk of recurrence or death versus KEYTRUDA alone, reinforcing Merck's strategic push in immuno-oncology alongside competitors such as Bristol Myers Squibb.

These long-run data are seen as important for Merck's pipeline narrative because they address high-risk melanoma patients who continue to face relapse risk despite surgery, and V940 plus KEYTRUDA is positioned as a next-wave modality within the KEYTRUDA franchise, which already drives a substantial portion of Merck's revenue base according to company disclosures at recent investor events.Merck investor presentation on KEYTRUDA and pipeline

Analyst view and consensus

On Wall Street, Merck is widely covered as a core S&P 500 large-cap pharma holding, and consensus data compiled by MarketBeat indicate that most analysts rate the stock at Buy or Overweight, with a blended 12?month target in the low- to mid?120 dollar range, implying moderate upside from the recent 115 dollar area for MRK shares on the NYSE.MarketBeat consensus and price data for MRK The same overview notes that MRK closed around 115.47 dollars on 2026-06-22, a level that reflects both the strength of KEYTRUDA and a late-stage pipeline that includes oncology, vaccines, and cardiovascular candidates.

Several major houses such as Morgan Stanley and JPMorgan have in recent months reiterated positive views on large-cap pharma defensives, citing resilient cash flows and dividend streams in an environment where investors compare Merck with peers like Pfizer and Johnson & Johnson, although individual rating details vary by firm and are regularly updated in their research reports.Reuters market commentary on US defensives including big pharma

How Merck makes its money

Merck & Co.'s business is anchored by the cancer therapy KEYTRUDA (pembrolizumab), which is approved across multiple tumor types and indications, alongside vaccines such as GARDASIL for human papillomavirus and the pneumococcal shot VAXNEUVANCE, forming a diversified portfolio that generated tens of billions of dollars in annual revenue in 2025 based on company reporting.

Where the shares trade now

The Merck & Co. shares (US58933Y1055) most recently changed hands on the NYSE at about 115.47 US dollars as of 2026-06-22, 15:59 New York time, according to consolidated exchange data.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results. Readers should conduct their own research and, where appropriate, consult a qualified financial advisor.